Aptose Biosciences(US:APTO)2025-03-28 12:42Financial Performance - For the year ended December 31, 2024, Aptose reported a net loss of $25.4 million, a decrease of $25.8 million compared to a net loss of $51.2 million in 2023[10]. - Research and development expenses decreased by $21.7 million to $15.1 million for the year ended December 31, 2024, compared to $36.8 million in 2023[13]. - As of December 31, 2024, cash, cash equivalents, and restricted cash equivalents totaled $6.7 million, down from $9.3 million in 2023[12]. - The program costs for tuspetinib were $9.6 million for the year ended December 31, 2024, compared to $24.9 million in 2023, reflecting reduced clinical trial activity[18]. Financing Activities - The company completed several financings totaling approximately $37 million in 2024, including a $10 million loan facility agreement with Hanmi Pharmaceutical[3]. - The company is negotiating a new co-development collaboration agreement with Hanmi to provide additional funding for tuspetinib's clinical development[3]. Clinical Development - The TUS+VEN+AZA triplet therapy achieved complete remissions in difficult-to-treat TP53-mutated AML and FLT3-wildtype AML patients during the ongoing TUSCANY trial[2]. - The company initiated dosing of the TUS+VEN+AZA triplet therapy in newly diagnosed AML patients in the TUSCANY trial, with a starting dose of 40 mg TUS[3]. - Aptose entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on the clinical development of tuspetinib[4]. Compliance and Governance - Aptose regained compliance with Nasdaq's minimum bid price requirement, with the closing bid price of its common shares being $1.00 or greater for ten consecutive business days[4].